Antitumor Activity of Theophylline in Combination with Paclitaxel: A Preclinical Study on Melanoma Experimental Lung Metastasis

被引:15
作者
Lentini, Alessandro [1 ]
Tabolacci, Claudio [1 ]
Mattioli, Palma [1 ]
Provenzano, Bruno [1 ]
Beninati, Simone [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy
关键词
B16-F10; melanoma; metastasis; paclitaxel; theophylline; DIFFERENTIATION THERAPY; BREAST-CANCER; CELL-DEATH; TAXOL; INHIBITION; CISPLATIN; LEUKEMIA; ANGIOGENESIS; CHEMOTHERAPY; MECHANISMS;
D O I
10.1089/cbr.2010.0787
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma is one of the most aggressive forms of tumor, being responsible for about 80% of skin cancer deaths. Much effort is being directed at obtaining less-toxic anticancer therapies, and the combination between low cytotoxic doses of chemotherapeutic drugs and natural differentiative compounds seems to be of particular importance. The present study was undertaken to examine the possible role of a combination therapy using paclitaxel (PTX) as chemotherapeutic molecule and theophylline (TH) as differentiative agent in the prevention of metastasis in B16-F10 melanoma-bearing C57BL6/N mice. In vitro proliferation studies demonstrated that TH enhanced the antiproliferative effect of PTX. In the in vivo experiments, a highly sensitive computerized image analysis method, performed on histological lung sections of mice injected with melanoma cells, was used to quantify the efficacy of the treatments. This study demonstrated that the simultaneous treatment of mice with TH and a low dose of PTX produced a similar anti-invasive effect than that caused by highly toxic PTX concentration.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 50 条
  • [31] Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer
    Tamura, Shigeyuki
    Miki, Hirofumi
    Okada, Kaoru
    Takeno, Atsushi
    Uji, Kumiko
    Yoshida, Atsuko
    Suzuki, Rei
    Nakahira, Shin
    Egawa, Chiyomi
    Nakata, Ken
    Okamura, Shu
    Sugimoto, Keishi
    Takatsuka, Yuichi
    GASTRIC CANCER, 2010, 13 (02) : 101 - 108
  • [32] Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
    Hirose, Takashi
    Sugiyama, Tomohide
    Kusumoto, Sojiro
    Shirai, Takao
    Nakashima, Masanao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ogura, Keiichi
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    ANTICANCER RESEARCH, 2009, 29 (05) : 1733 - 1738
  • [33] Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer
    Xie, Cheng-Ying
    Xu, Yong-Ping
    Jin, Wei
    Lou, Li-Guang
    ANTI-CANCER DRUGS, 2012, 23 (07) : 698 - 705
  • [34] Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model
    Kim, Yu-Yon
    Park, Hyunjin
    Song, Taehun
    Choi, Kyungjin
    Dolton, Michael
    Mao, Jialin
    Kim, Jisook
    Ahn, Young Gil
    Suh, Kwee Hyun
    Kim, Young Hoon
    CLINICAL & EXPERIMENTAL METASTASIS, 2023, 40 (02) : 137 - 148
  • [35] Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity
    Han, Bing
    Yang, Yue
    Chen, Jinglin
    Tang, Huan
    Sun, Yuxin
    Zhang, Zheng
    Wang, Zeng
    Li, Yan
    Li, Yao
    Luan, Xue
    Li, Qianwen
    Ren, Zhihui
    Zhou, Xiaowei
    Cong, Dengli
    Liu, Zhiyi
    Meng, Qin
    Sun, Fei
    Pei, Jin
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2020, 15 : 553 - 571
  • [36] Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity
    Choudhury, Hira
    Gorain, Bapi
    Tekade, Rakesh Kumar
    Pandey, Manisha
    Karmakar, Sanmoy
    Pal, Tapan Kumar
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 91 : 179 - 189
  • [37] Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
    Asano, Makoto
    Matsui, Junji
    Towle, Murray J.
    Wu, Jiayi
    Mcgonigle, Sharon
    De Boisferon, Marc Hillairet
    Uenaka, Toshimitsu
    Nomoto, Kenichi
    Littlefield, Bruce A.
    ANTICANCER RESEARCH, 2018, 38 (06) : 3375 - 3385
  • [38] Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo
    Fujimoto, S
    Chikazawa, H
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (12): : 1343 - 1351
  • [39] A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma
    Kosmas, C
    Tsavaris, NB
    Polyzos, A
    Kalofonos, HP
    Sepsas, E
    Malamos, NA
    Vadiaka, M
    Dosios, T
    Antonopoulos, MJ
    CANCER, 2000, 89 (04) : 774 - 782
  • [40] A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies
    Huang, Wei-Jan
    Tang, Yen-An
    Chen, Mei-Yu
    Wang, Ying-Jan
    Hu, Fu-Han
    Wang, Tseng-Wei
    Chao, Shi-Wei
    Chiu, Hui-Wen
    Yeh, Ya-Ling
    Chang, Hsin-Yi
    Juan, Hsueh-Fen
    Lin, Pinpin
    Wang, Yi-Ching
    CANCER LETTERS, 2014, 346 (01) : 84 - 93